1061 related articles for article (PubMed ID: 27296652)
1. Individualized network-based drug repositioning infrastructure for precision oncology in the panomics era.
Cheng F; Hong H; Yang S; Wei Y
Brief Bioinform; 2017 Jul; 18(4):682-697. PubMed ID: 27296652
[TBL] [Abstract][Full Text] [Related]
2. In Silico Oncology Drug Repositioning and Polypharmacology.
Cheng F
Methods Mol Biol; 2019; 1878():243-261. PubMed ID: 30378081
[TBL] [Abstract][Full Text] [Related]
3. Systems Pharmacology-Based Discovery of Natural Products for Precision Oncology Through Targeting Cancer Mutated Genes.
Fang J; Cai C; Wang Q; Lin P; Zhao Z; Cheng F
CPT Pharmacometrics Syst Pharmacol; 2017 Mar; 6(3):177-187. PubMed ID: 28294568
[TBL] [Abstract][Full Text] [Related]
4. Advances in computational approaches for prioritizing driver mutations and significantly mutated genes in cancer genomes.
Cheng F; Zhao J; Zhao Z
Brief Bioinform; 2016 Jul; 17(4):642-56. PubMed ID: 26307061
[TBL] [Abstract][Full Text] [Related]
5. A computational method for clinically relevant cancer stratification and driver mutation module discovery using personal genomics profiles.
Wang L; Li F; Sheng J; Wong ST
BMC Genomics; 2015; 16 Suppl 7(Suppl 7):S6. PubMed ID: 26099165
[TBL] [Abstract][Full Text] [Related]
6. Implementing Genome-Driven Oncology.
Hyman DM; Taylor BS; Baselga J
Cell; 2017 Feb; 168(4):584-599. PubMed ID: 28187282
[TBL] [Abstract][Full Text] [Related]
7. Outlier analysis of functional genomic profiles enriches for oncology targets and enables precision medicine.
Zhu Z; Ihle NT; Rejto PA; Zarrinkar PP
BMC Genomics; 2016 Jun; 17():455. PubMed ID: 27296290
[TBL] [Abstract][Full Text] [Related]
8. Implementing precision cancer medicine in the genomic era.
Chen HZ; Bonneville R; Roychowdhury S
Semin Cancer Biol; 2019 Apr; 55():16-27. PubMed ID: 29857039
[TBL] [Abstract][Full Text] [Related]
9. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
Paolillo C; Londin E; Fortina P
Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
[TBL] [Abstract][Full Text] [Related]
10. A survey of current trends in computational drug repositioning.
Li J; Zheng S; Chen B; Butte AJ; Swamidass SJ; Lu Z
Brief Bioinform; 2016 Jan; 17(1):2-12. PubMed ID: 25832646
[TBL] [Abstract][Full Text] [Related]
11. Genomics-Enabled Precision Medicine for Cancer.
Roos A; Byron SA
Cancer Treat Res; 2019; 178():137-169. PubMed ID: 31209844
[TBL] [Abstract][Full Text] [Related]
12. Computational drug repositioning for rare diseases in the era of precision medicine.
Delavan B; Roberts R; Huang R; Bao W; Tong W; Liu Z
Drug Discov Today; 2018 Feb; 23(2):382-394. PubMed ID: 29055182
[TBL] [Abstract][Full Text] [Related]
13. MD-Miner: a network-based approach for personalized drug repositioning.
Wu H; Miller E; Wijegunawardana D; Regan K; Payne PRO; Li F
BMC Syst Biol; 2017 Oct; 11(Suppl 5):86. PubMed ID: 28984195
[TBL] [Abstract][Full Text] [Related]
14. Top advances of the year: Precision oncology.
Desai A; Reddy NK; Subbiah V
Cancer; 2023 Jun; 129(11):1634-1642. PubMed ID: 36946766
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive genomic profiling for oncological advancements by precision medicine.
Pankiw M; Brezden-Masley C; Charames GS
Med Oncol; 2023 Nov; 41(1):1. PubMed ID: 37993657
[TBL] [Abstract][Full Text] [Related]
16. Systematic Prioritization of Druggable Mutations in ∼5000 Genomes Across 16 Cancer Types Using a Structural Genomics-based Approach.
Zhao J; Cheng F; Wang Y; Arteaga CL; Zhao Z
Mol Cell Proteomics; 2016 Feb; 15(2):642-56. PubMed ID: 26657081
[TBL] [Abstract][Full Text] [Related]
17. Exploiting rare driver mutations for precision cancer medicine.
Scholl C; Fröhling S
Curr Opin Genet Dev; 2019 Feb; 54():1-6. PubMed ID: 30844512
[TBL] [Abstract][Full Text] [Related]
18. State of the art discovery with tumor profiling in pediatric oncology.
Carroll WL; Raetz E; Meyer J
Am Soc Clin Oncol Educ Book; 2015; ():e601-7. PubMed ID: 25993229
[TBL] [Abstract][Full Text] [Related]
19. A network-based drug repositioning infrastructure for precision cancer medicine through targeting significantly mutated genes in the human cancer genomes.
Cheng F; Zhao J; Fooksa M; Zhao Z
J Am Med Inform Assoc; 2016 Jul; 23(4):681-91. PubMed ID: 27026610
[TBL] [Abstract][Full Text] [Related]
20. Computational and experimental advances in drug repositioning for accelerated therapeutic stratification.
Shameer K; Readhead B; Dudley JT
Curr Top Med Chem; 2015; 15(1):5-20. PubMed ID: 25579574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
